Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration
Charlotte Sonigo, … , Jacques Young, Nadine Binart
Charlotte Sonigo, … , Jacques Young, Nadine Binart
Published September 24, 2012
Citation Information: J Clin Invest. 2012;122(10):3791-3795. https://doi.org/10.1172/JCI63937.
View: Text | PDF
Brief Report Article has an altmetric score of 3

Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration

  • Text
  • PDF
Abstract

Hyperprolactinemia is the most common cause of hypogonadotropic anovulation and is one of the leading causes of infertility in women aged 25–34. Hyperprolactinemia has been proposed to block ovulation through inhibition of GnRH release. Kisspeptin neurons, which express prolactin receptors, were recently identified as major regulators of GnRH neurons. To mimic the human pathology of anovulation, we continuously infused female mice with prolactin. Our studies demonstrated that hyperprolactinemia in mice induced anovulation, reduced GnRH and gonadotropin secretion, and diminished kisspeptin expression. Kisspeptin administration restored gonadotropin secretion and ovarian cyclicity, suggesting that kisspeptin neurons play a major role in hyperprolactinemic anovulation. Our studies indicate that administration of kisspeptin may serve as an alternative therapeutic approach to restore the fertility of hyperprolactinemic women who are resistant or intolerant to dopamine agonists.

Authors

Charlotte Sonigo, Justine Bouilly, Nadège Carré, Virginie Tolle, Alain Caraty, Javier Tello, Fabian-Jesus Simony-Conesa, Robert Millar, Jacques Young, Nadine Binart

×

Figure 1

Effects of PRL infusion with daily injection of PBS or Kp on 6-week-old adult female mice.

Options: View larger image (or click on image) Download as PowerPoint
Effects of PRL infusion with daily injection of PBS or Kp on 6-week-old ...
(A) Estrous cycle profiles of a single representative mouse from control, PRL, and PRL+Kp groups over 28 days. Each stage of the estrous cycle was determined by daily vaginal smears. Lines under each diagram represent daily intraperitoneal injections of Kp or PBS as control in mice treated with PRL. (B) Mean cycle numbers during 21 days. PRL mice (n = 12) had significantly fewer cycles than control (n = 21) and Kp-treated mice (n = 19). ***P < 0.0001. (C) Representative ovarian histological sections from each group. Asterisks indicate corpora lutea, reflecting ovulation rate. (D) Mean number of corpora lutea in both ovaries at the end of the experiment. Analysis revealed a marked decrease in corpora lutea in the PRL group (n = 6) versus the control (n = 8) and PRL+Kp groups (n = 19). ***P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
On 1 Facebook pages
Mentioned in 1 Google+ posts
Highlighted by 1 platforms
115 readers on Mendeley
See more details